References
- Angiolillo DJ, Weisman SM. Clinical pharmacology and cardiovascular safety of naproxen. Am J Cardiovasc Drugs. 2017;17(2):97-107.
- Moore N, Scheiman JM. Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesics. Postgrad Med J. 2018;130(2):188-99.
- Katritzky AR, Jishkariani D, Narindoshvili T. Convenient synthesis of ibuprofen and naproxen aminoacyl, dipeptidoyl and ester derivatives. Chem Biol Drug Des. 2009;73(6):618–26.
- Piffar P, Fernandez R, Tchaikovski O Jr, Hirabara SM, Folador A, Pinto GJ, et al. Naproxen, clenbuterol and insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats. Cancer Lett. 2003;201(2):139–48.
- Chen PC, Patil V, Guerrant W, Green P, Oyelere AK. Synthesis and structure–activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Bioorg Med Chem. 2008;16(9): 4839–53.
- Khalifa MM, Ismail MM, Eissa S, Ammar Y. Design and synthesis, of some novel 6-methoxynaphthalene derivatives with potential anticancer activity. Der Pharma Chem. 2012;4(4):1552–66.
- Kumar V, Chimni SS. Recent developments on thiourea based anticancer chemotherapeutics. Anti-Cancer Agents Med Chem. 2015;15(2):163-75.
- Prajapati NP, Patel HD. Novel thiosemicarbazone derivatives and their metal complexes: Recent development. Synth Commun. 2019;49(21):2767-804.
- Lourenco AL, Saito MS, Dorneles LE, Viana GM, Sathler PC, Aguiar LC, et al. Synthesis and antiplatelet activity of antithrombotic thiourea compounds: biological and structure-activity relationship studies. Molecules. 2015;20(4):7174-200.
- Liu W, Zhou J, Zhang T, Zhu H, Qian H, Zhang H, et al. Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents. Bioorg Med Chem Lett. 2012;22:2701-4.
- Shakeel A. Thiourea Derivatives in Drug Design and Medicinal Chemistry: A Short Review. J Drug Des Med Chem. 2016;2:10.
- Hu H, Lin C, Ao M, Ji Y, Tang B, Zhou X, et al. Synthesis and biological evaluation of 1-(2-(adamantane-1-yl)-1H-indol-5-yl)-3-substituted urea/thiourea derivatives as anticancer agents. RSC Adv. 2017;7:51640-51.
- Pingaew R, Sinthupoom N, Mandi P, Prachayasittikul V, Cherdtrakulkiat R, Prachayasittikul S, et al. Synthesis, biological evaluation and in silico study of bis-thiourea derivatives as anticancer, antimalarial and antimicrobial agents. Med Chem Res. 2017;26:3136-48.
- Zhang H, Zhang Y, Wu G, Zhou J, Huang W, Hu X. Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents. Bioorg Med Chem Lett. 2009;19:1740-4.
- Nordin NA, Chai TW, Tan BL, Choi CL, Abd Halim AN, Hussain H, et al. Novel synthetic monothiourea aspirin derivatives bearing alkylated amines as potential antimicrobial agents. J Chem. 2017;2017.
- Li J, Tan JZ, Chen LL, Zhang J, Shen X, Mei CL, et al. Design, synthesis and antitumor evaluation of a new series of N‐substituted‐thiourea derivatives 1. Acta Pharmacol Sin. 2006;27(9):1259-71.
- Lu PC, Li HQ, Sun J, Zhou Y, Zhu HL. Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents. Bioorg Med Chem. 2010;18(13):4606-14.
- Yao J, Chen J, He Z, Sun W, Xu W. Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents. Bioorg Med Chem. 2012;20(9):2923-9.
- Li HQ, Yan T, Yang Y, Shi L, Zhou CF, Zhu HL. Synthesis and structure–activity relationships of N-benzyl-N-(X-2-hydroxybenzyl)-N′-phenylureas and thioureas as antitumor agents. Bioorg Med Chem. 2010;18:305-13.
- Zhao Y, Wang C, Wu Z, Fang J, Zhu L. Synthesis and antitumor activity of novel aroylthiourea derivatives of podophyllotoxin. Invest New Drugs. 2012;30:17-24.
- Moeker J, Teruya K, Rossit S, Wilkinson BL, Lopez M, Bornaghi LF, et al. Design and synthesis of thiourea compounds that inhibit transmembrane anchored carbonic anhydrases. Bioorg Med Chem. 2012;20(7):2392-404.
- Huhtiniemi T, Suuronen T, Rinne VM, Wittekindt C, Kakkonen ML, Jarho E, et al; Leppanen, J. Oxadiazolecarbonylaminothioureas as SIRT1 and SIRT2 inhibitors. J Med Chem. 2008;51:4377-80.
- Gagic Z, Ruzic D, Djokovic N, Djikic T, Nikolic K. In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs. Front Chem. 2020;7:873.
- Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018;17(5):353-77.
- Akhtar MJ, Siddiqui AA, Khan AA, Ali Z, Dewangan RP, Pasha S, et al. Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors. Eur J Med Chem. 2017;126:853-69.
- Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract. 2005;14:35–48.
- Wu Q, Yang Z, Nie Y, Shi Y, Fan D. Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett. 2014;347:159–66.
- Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2:141–160.
- Dallavalle S, Dobričić V, Lazzarato L, Gazzano E, Machuqueiro M, Pajeva I, et al. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist Updat. 2020; 50: 100682.
- Jin Y, Zhang W, Xu J, Wang H, Zhang Z, Chu C, et al. UCH-L1 involved in regulating the degradation of EGFR and promoting malignant properties in drug-resistant breast cancer. Int J Clin Exp Pathol. 2015;8(10):12500–8.
- To KK, Poon DC, Wei Y, Wang F, Lin G, Fu LW. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia. Biochem pharmacol. 2015;97(1):27-37.
- Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):1-2.
- Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003;22(21):3205-12.
- ChemOffice Ultra 7.0.1, 2002, CambridgeSoft Corporation, Cambridge, MA, USA (http://www.cambridgesoft.com).
- Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDock-Tools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16): 2785-91.
- OMEGA 2.5.1.4: OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com/.
- Hawkins PCD, Skillman AG, Warren GL, Ellingson BA, Stahl MT. Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and the Cambridge Structural Database. J Chem Inf Model. 2010;50:572-84.
- BIOVIA, Dassault Systèmes, Discovery Studio Visualizer, 17.2.0.16349, San Diego: Dassault Systèmes, 2016.
- MAKE Receptor 3.2.0.2: OpenEye Scientific Software, Santa Fe, NM. https://www.eyesopen.com/.
- Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J comput chem. 2010;31(2):455-61.
- FRED 3.2.0.2: OpenEye Scientific Software, Santa Fe, NM. https://www.eyesopen.com/.
- McGann M. FRED pose prediction and virtual screening accuracy. J Chem Inf Model. 2011;51:578-96.
- McGann M. FRED and HYBRID docking performance on standardized datasets. J Comput Aided Mol Des. 2012; 26: 897-906.
- Macrae CF, Edgington PR, McCabe P, Pidcock E, Shields GP, Taylor R, et al. Mercury: visualization and analysis of crystal structures. J Appl Crystallogr. 2006;39(3):453-7.
- Protein Data Bank available at http://www.rcsb.org/
- Carugo O, Pongor S. A normalized root-mean-spuare distance for comparing protein three-dimensional structures. Protein Sci. 2001;10(7):1470-3.
- Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 2002;277(48):46265-72.
- Widiandani T, Siswandono S, Meiyanto E, Sulistyowaty MI, Purwanto BT, Hardjono S. New N-allylthiourea derivatives: synthesis, molecular docking and in vitro cytotoxicity studies. Trop J Pharm Res. 2018;17(8):1607-13.
- Rouse MB, Seefeld MA, Leber JD, McNulty KC, Sun L, Miller WH, et al. Aminofurazans as potent inhibitors of AKT kinase. Bioorg Med Chem Lett. 2009;19(5):1508-11.
- Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature. 2013;497(7448):217-23.